

Alexis Ogdie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4616516/publications.pdf>

Version: 2024-02-01

217
papers

10,350
citations

71004

43
h-index

45040

94
g-index

232
all docs

232
docs citations

232
times ranked

9039
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Factors for Diagnosis of Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and Ankylosing Spondylitis: A Set of Parallel Case-control Studies. <i>Journal of Rheumatology</i> , 2022, 49, 53-59.	1.0	19
2	Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study. <i>Rheumatology</i> , 2022, 61, 1877-1884.	0.9	20
3	Evaluation of Clinical Diagnosis of Axial Psoriatic Arthritis (PsA) or Elevated Patient-reported Spine Pain in CorEvitas™ PsA/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2022, 49, 281-290.	1.0	9
4	Does biologic therapy impact the development of PsA among patients with psoriasis?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 80-86.	0.5	29
5	Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. <i>JAMA Dermatology</i> , 2022, 158, 252.	2.0	15
6	Association between depression, anxiety, chronic pain, or opioid use and tumor necrosis factor inhibitor persistence in inflammatory arthritis. <i>Clinical Rheumatology</i> , 2022, , 1.	1.0	3
7	Usage of C-Reactive Protein Testing in the Diagnosis and Monitoring of Psoriatic Arthritis (PsA): Results from a Real-World Survey in the USA and Europe. <i>Rheumatology and Therapy</i> , 2022, 9, 285-293.	1.1	8
8	Time to transition from psoriasis to psoriatic arthritis: A population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151949.	1.6	6
9	Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 206-217.	0.5	1
10	Psoriatic arthritis: prospects for the future. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210867.	1.2	4
11	Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2022, , jrheum.211322.	1.0	1
12	Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry. <i>Rheumatology and Therapy</i> , 2022, 9, 735-751.	1.1	5
13	Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting. <i>Journal of Rheumatology</i> , 2022, , jrheum.211328.	1.0	0
14	OUP accepted manuscript. <i>Rheumatology</i> , 2022, , .	0.9	4
15	Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence. <i>Rheumatology and Therapy</i> , 2022, 9, 803-821.	1.1	11
16	Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. <i>Journal of Rheumatology</i> , 2022, 49, 885-893.	1.0	12
17	Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, 49, 694-699.	1.0	4
18	Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2022, 49, 700-706.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study. <i>Journal of Rheumatology</i> , 2022, 49, 894-902.	1.0	7
20	Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, , jrheum.211337.	1.0	0
21	P266â€fSecukinumab provides clinical improvements in patients with active oligoarticular psoriatic arthritis: results from a pooled analysis of five phase 3 studies. <i>Rheumatology</i> , 2022, 61, .	0.9	0
22	Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons Living With Psoriatic Disease. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022, 7, 174-186.	0.3	3
23	Drs. Meer and Ogdie reply. <i>Journal of Rheumatology</i> , 2022, 49, 1179-1179.	1.0	0
24	Disease Characteristics, Quality of Life, and Work Productivity by Enthesitis Site: Real-world Data From the US Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2021, 48, 367-375.	1.0	11
25	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 58-66.	1.0	5
26	Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2021, 48, 520-526.	1.0	14
27	Age-appropriate cancer screening: A cohort study of adults with psoriasis prescribed biologics, adults in the general population, and adults with hypertension. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1602-1609.	0.6	6
28	Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. <i>Journal of Rheumatology</i> , 2021, 48, 693-697.	1.0	10
29	Effect of Multidomain Disease Presentations on Patients With Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2021, 48, 698-706.	1.0	15
30	A comparison of physical function instruments in psoriatic arthritis: HAQ-DI <i>vs</i> MDHAQ <i>vs</i> PROMIS10 global physical health. <i>Rheumatology</i> , 2021, 60, 2307-2316.	0.9	9
31	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 1137-1147.	0.9	13
32	Psoriatic arthritis and the association with cardiometabolic disease: a narrative review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2199827.	1.2	31
33	Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001486.	1.8	24
34	Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 566-572.	0.5	18
35	Diagnostic Delay in Psoriatic Arthritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2021, 48, 1410-1416.	1.0	25
36	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. <i>Nature Reviews Rheumatology</i> , 2021, 17, 238-243.	3.5	23

#	ARTICLE	IF	CITATIONS
37	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2021, , jrheum.201679.	1.0	2
38	The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. <i>Clinical Rheumatology</i> , 2021, 40, 3667-3677.	1.0	3
39	Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201668.	1.0	8
40	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 367-386.	1.6	2
41	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1547-1551.	1.0	3
42	Comparison of Men and Women With Axial Spondyloarthritis in the US-based Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2021, 48, 1528-1536.	1.0	44
43	AB0892-HPRâ€...PATIENT PERSPECTIVES ON PROVIDER PRACTICES LEADING TO AN AXIAL SPONDYLOARTHRITIS DIAGNOSIS: A QUALITATIVE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1469.2-1470.	0.5	0
44	OPO231â€...DIFFERENCES IN REAL-WORLD PATIENT CHARACTERISTICS OF 8921 PSORIASIS PATIENTS WITH AND WITHOUT COMORBID PSORIATIC ARTHRITIS USING THE UK BADBIR DATABASE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 141-141.	0.5	0
45	POS1052â€...PSORIATIC ARTHRITIS AND OBESITY IMPACT DRUG PERSISTENCE IN USTEKINUMAB-TREATED PATIENTS WITH PSORIASIS IN THE BRITISH ASSOCIATION OF DERMATOLOGISTS BIOLOGIC AND IMMUNOMODULATORS REGISTER (BADBIR): A 10-YEAR FOLLOW-UP STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 804-805.	0.5	0
46	Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1726.	3.8	9
47	POS1063â€...RHEUMATOLOGIST AND PATIENT PERSPECTIVES ON IMPLEMENTING CARDIOVASCULAR RISK PREVENTION IN THE MANAGEMENT OF PSORIASIS: A QUALITATIVE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 810.2-810.	0.5	1
48	AB0560â€...EFFECT OF DEUCRAVACITINIB ON THE PSORIATIC ARTHRITIS IMPACT OF DISEASE (PsAID) QUESTIONNAIRES 12 AND 9: ANALYSIS OF A PHASE 2 STUDY OF ACTIVE PSORIATIC ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1316-1317.	0.5	2
49	Personal Experiences with Diagnostic Delay Among Axial Spondyloarthritis Patients: A Qualitative Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1015-1030.	1.1	9
50	POS1474-HPRâ€...PERSONAL EXPERIENCES WITH DIAGNOSTIC DELAY AMONG AXIAL SPONDYLOARTHRITIS PATIENTS â€ A QUALITATIVE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1022.2-1022.	0.5	0
51	POS0062-PAREâ€...REAL-WORLD PATIENT EXPERIENCE AND TREATMENT PREFERENCES IN PATIENTS WITH PSORIATIC ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 237.2-238.	0.5	0
52	AB0553â€...BASELINE DISEASE ACTIVITY AS A PREDICTOR FOR ACHIEVING cDAPSA TREATMENT TARGETS WITH APREMILAST IN DMARD-NAIVE PATIENTS WITH MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1311-1311.	0.5	1
53	The epidemiology of psoriatic arthritis: A literature review. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101692.	1.4	44
54	Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1636-1643.	0.6	34

#	ARTICLE	IF	CITATIONS
55	Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. RMD Open, 2021, 7, e001609.	1.8	4
56	Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis. Arthritis and Rheumatology, 2021, 73, 1574-1578.	2.9	6
57	The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population-Based Study. Arthritis and Rheumatology, 2021, 73, 1878-1885.	2.9	25
58	Psoriatic arthritis. Nature Reviews Disease Primers, 2021, 7, 59.	18.1	113
59	Socioeconomic Disparities in Functional Status in a National Sample of Patients With Rheumatoid Arthritis. JAMA Network Open, 2021, 4, e2119400.	2.8	29
60	Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores. Clinical Trials, 2021, 18, 541-551.	0.7	0
61	Racial Differences in Prevalence and Treatment for Psoriatic Arthritis and Ankylosing Spondylitis by Insurance Coverage in the USA. Rheumatology and Therapy, 2021, 8, 1725-1739.	1.1	11
62	Real-World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study. ACR Open Rheumatology, 2021, , .	0.9	5
63	Dr. Mease et al reply. Journal of Rheumatology, 2021, 48, jrheum.210750.	1.0	1
64	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. Seminars in Arthritis and Rheumatism, 2021, 51, 1117-1124.	1.6	4
65	Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis. Arthritis Research and Therapy, 2021, 23, 252.	1.6	11
66	Does psoriasis treatment affect PsA development?. Nature Reviews Rheumatology, 2021, 17, 708-709.	3.5	8
67	Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination. , 2021, 3, e0578.		11
68	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD Open, 2021, 7, e001845.	1.8	11
69	Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. Journal of Rheumatology, 2020, 47, 1496-1505.	1.0	14
70	Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Journal of Rheumatology, 2020, 47, 826-834.	1.0	17
71	Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). Rheumatology, 2020, 59, 1495-1504.	0.9	18
72	Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. Journal of the American Academy of Dermatology, 2020, 82, 54-61.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Treatmentâ€”Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. <i>Arthritis Care and Research</i> , 2020, 72, 814-821.	1.5	6
74	Changing health behaviours in rheumatology: an introduction to behavioural economics. <i>Nature Reviews Rheumatology</i> , 2020, 16, 53-60.	3.5	14
75	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa032.	0.3	3
76	Persistent premature mortality gap in dermatomyositis and polymyositis: a United Kingdom general population-based cohort study. <i>Rheumatology</i> , 2020, 60, 2653-2660.	0.9	8
77	COVIDâ€”19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Diseaseâ€”Modifying Antirheumatic Drugs on Clinical Outcomes. <i>Arthritis and Rheumatology</i> , 2020, 72, 1981-1989.	2.9	92
78	Measuring Outcomes in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 82-109.	1.5	11
79	Measuring Outcomes in Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2020, 72, 47-71.	1.5	11
80	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1158-1181.	1.6	6
81	Micronutrients: Essential Treatment for Inflammatory Arthritis?. <i>Current Rheumatology Reports</i> , 2020, 22, 87.	2.1	6
82	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. <i>Current Rheumatology Reports</i> , 2020, 22, 78.	2.1	10
83	Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2020, 2, 543-554.	0.9	7
84	Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis. <i>BMC Rheumatology</i> , 2020, 4, 39.	0.6	9
85	Physical Activity Patterns in People With Inflammatory Arthritis Indicate They Have not Received Recommendationâ€”Based Guidance From Health Care Providers. <i>ACR Open Rheumatology</i> , 2020, 2, 582-587.	0.9	9
86	Probiotic Use and Psoriatic Arthritis Disease Activity. <i>ACR Open Rheumatology</i> , 2020, 2, 330-334.	0.9	7
87	Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>RMD Open</i> , 2020, 6, e001042.	1.8	18
88	Obesity and Psoriatic Arthritis: A Narrative Review. <i>Rheumatology and Therapy</i> , 2020, 7, 447-456.	1.1	38
89	Treatment guidelines in psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, i37-i46.	0.9	111
90	Risk of Malignancy in Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 463-511.	0.8	12

#	ARTICLE	IF	CITATIONS
91	Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>ACR Open Rheumatology</i> , 2020, 2, 449-456.	0.9	22
92	The need for strategies to address obesity and psoriatic arthritis prevention in psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, 523-524.	1.4	5
93	Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 267-283.	1.3	2
94	Patient perspectives on the pathway to psoriatic arthritis diagnosis: results from a web-based survey of patients in the United States. <i>BMC Rheumatology</i> , 2020, 4, 2.	0.6	23
95	Reliability and Validity of Patient-reported Outcomes Measurement Information System Short Forms in Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2020, 47, 1182-1188.	1.0	12
96	Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic. <i>ACR Open Rheumatology</i> , 2020, 2, 335-343.	0.9	131
97	AB0778â€¦ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND DISEASE ACTIVITY IN BIMEKIZUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1687.1-1687.	0.5	4
98	OP0247â€¦PERSISTENT PREMATURE MORTALITY GAP IN IDIOPATHIC INFLAMMATORY MYOPATHY: A GENERAL POPULATION-BASED COHORT STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 155.1-156.	0.5	0
99	SAT0404â€¦INCIDENCE OF PSORIATIC ARTHRITIS FROM 2000-2017: A POPULATION-BASED STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1154.1-1154.	0.5	0
100	FRI0356â€¦BURDEN OF DISEASE IN PATIENTS INITIATING APREMILAST TREATMENT: 2014-2019 FINDINGS FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRTIS REGISTRY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 774-775.	0.5	1
101	FRI0358â€¦USAGE OF C-REACTIVE PROTEIN TESTING IN THE DIAGNOSIS AND MONITORING OF PSORIATIC ARTHRITIS (PSA): RESULTS FROM A REAL-WORLD SURVEY IN THE US AND EUROPE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 775.2-776.	0.5	0
102	AB0818â€¦SKIN INVOLVEMENT IN PSORIATIC ARTHRITIS (PsA) - THE INCREMENTAL IMPACT OF PSORIASIS ON QUALITY OF LIFE, DISABILITY AND WORK PRODUCTIVITY: REAL-WORLD SURVEY IN US AND EUROPE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1711.2-1712.	0.5	0
103	Patientâ€™s experience of psoriatic arthritis: a conceptual model based on qualitative interviews. <i>RMD Open</i> , 2020, 6, e001321.	1.8	21
104	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. <i>Journal of Rheumatology</i> , 2019, 46, 475-482.	1.0	31
105	Real-World Patient Experience on the Path to Diagnosis of Ankylosing Spondylitis. <i>Rheumatology and Therapy</i> , 2019, 6, 255-267.	1.1	32
106	Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. <i>JAMA Dermatology</i> , 2019, 155, 700.	2.0	43
107	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	1.0	36
108	Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. <i>Nature Reviews Rheumatology</i> , 2019, 15, 153-166.	3.5	208

#	ARTICLE	IF	CITATIONS
109	<sc>SEAM</sc>â€œPsA: Seems Like Methotrexate Works in Psoriatic Arthritis?. Arthritis and Rheumatology, 2019, 71, 1027-1029.	2.9	8
110	AB0741â€œ...ACHIEVEMENT OF CDAPSA LOW DISEASE ACTIVITY OR REMISSION IS ASSOCIATED WITH CONTROL OF ARTICULAR AND EXTRA-ARTICULAR MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN SUBJECTS TREATED WITH APREMILAST. , 2019, , .		1
111	FRIO463â€œ...ENTHESITIS, DACTYLITIS, AND AXIAL DISEASE IN PSORIATIC ARTHRITIS (PSA): IMPACT ON PATIENT QUALITY OF LIFE AND WORK PRODUCTIVITY. , 2019, , .		2
112	FRIO460â€œ...IMPACT OF MULTIDOMAIN DISEASE PRESENTATIONS ON OVERALL DISEASE BURDEN AMONG PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY. , 2019, , .		1
113	AB0768â€œ...BASELINE PAIN SEVERITY AS A PREDICTOR OF PAIN IMPROVEMENT FOLLOWING TREATMENT WITH TOFACITINIB IN PSORIATIC ARTHRITIS. , 2019, , .		0
114	THU0397â€œ...CLINICAL CHARACTERISTICS AND TREATMENT PROFILES OF PATIENTS WITH ANKYLOSING SPONDYLITIS WHO INITIATED SECUKINUMAB AND OTHER BIOLOGICS: RESULTS FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY. , 2019, , .		0
115	FRIO429â€œ...NON TOPICAL PHARMACOLOGICAL TREATMENT OF EARLY, UNTREATED (DMARD-NAÏVE, SYSTEMIC) Tj ETQq1 0 0.7843		0
116	FRIO462â€œ...UNDERSTANDING MEDIATORS OF PAIN REDUCTION IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH TOFACITINIB: ROLE OF INFLAMMATION. , 2019, , .		0
117	SAT0343â€œ...BURDEN OF DISEASE AT TREATMENT INITIATION AMONG BIOLOGIC-NAVE PATIENTS WITH OLIGOARTICULAR VERSUS POLYARTICULAR PSORIATIC ARTHRITIS IN THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS REGISTRY. , 2019, , .		1
118	FRIO459â€œ...PREVALENCE OF DISEASE DOMAIN PRESENTATIONS AMONG PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY. , 2019, , .		1
119	SAT0367â€œ...PSAID9 IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH FILGOTINIB VS PLACEBO: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY. , 2019, , .		0
120	AB0767â€œ...MULTI-SYMPTOM IMPACT ON THE EQ-5D INDEX IN BIO-NAÏVE ACTIVE PSORIATIC ARTHRITIS PATIENTS: AN ANALYSIS THROUGH WEEK 24 OF THE GO-VIBRANT STUDY. , 2019, , .		0
121	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. Journal of Rheumatology, 2019, 46, 990-995.	1.0	43
122	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2019, 4, 31-58.	0.3	12
123	Impact of Industry Payments on Prescribing Patterns for Tumor Necrosis Factor Inhibitors Among Medicare Beneficiaries. Journal of General Internal Medicine, 2019, 34, 176-178.	1.3	8
124	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis and Rheumatology, 2019, 71, 5-32.	2.9	312
125	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care and Research, 2019, 71, 2-29.	1.5	264
126	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. Journal of Rheumatology, 2019, 95, 33-37.	1.0	14

#	ARTICLE	IF	CITATIONS
127	Incidence of <i>Pneumocystis jirovecii</i> and Adverse Events Associated With <i>Pneumocystis</i> Prophylaxis in Children Receiving Glucocorticoids. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 283-289.	0.6	5
128	Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 638-647.	1.0	14
129	Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1726-1735.	0.3	57
130	Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. <i>European Heart Journal</i> , 2018, 39, 3608-3614.	1.0	115
131	Barriers and Facilitators of Mentoring for Trainees and Early Career Investigators in Rheumatology Research: Current State, Identification of Needs, and Road Map to an Interinstitutional Adult Rheumatology Mentoring Program. <i>Arthritis Care and Research</i> , 2018, 70, 445-453.	1.5	12
132	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
133	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e23-e23.	0.5	16
134	Risk of Incident Liver Disease in Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: A Population-Based Study. <i>Journal of Investigative Dermatology</i> , 2018, 138, 760-767.	0.3	75
135	Discordance of the Framingham cardiovascular risk score and the 2013 American College of Cardiology/American Heart Association risk score in systemic lupus erythematosus and rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 467-474.	1.0	21
136	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	1.6	50
137	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	2.9	72
138	Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 119-123.	0.5	67
139	Potential risk factors for reactive arthritis and persistence of symptoms at 2 years: a case-control study with longitudinal follow-up. <i>Clinical Rheumatology</i> , 2018, 37, 415-422.	1.0	7
140	Frequency and Predictors of Communication About High Blood Pressure in Rheumatoid Arthritis Visits. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 210-217.	0.5	6
141	SAT0317...Tofacitinib in patients with psoriatic arthritis and metabolic syndrome: a post-hoc analysis of phase 3 studies. , 2018, , .		0
142	FRI0180...Diagnosis journey of patients with ankylosing spondylitis in the united states. , 2018, , .		0
143	Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics. <i>Current Rheumatology Reports</i> , 2018, 20, 76.	2.1	22
144	Pediatric Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2018, 3, 131-136.	0.3	22

#	ARTICLE	IF	CITATIONS
145	Classification and Outcome Measures for Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 246.	1.2	20
146	Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. <i>Archives of Dermatological Research</i> , 2018, 310, 701-710.	1.1	10
147	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	1.0	10
148	AB0849â€¦Correlation between rapid3 and promis10 in patients with ankylosing spondylitis. , 2018, , .		0
149	AB0904â€¦Correlation of rapid3 and promis10 in patients with psoriatic arthritis. , 2018, , .		0
150	GRAPPA 2017 Project Report. <i>Journal of Rheumatology</i> , 2018, 94, 48-51.	1.0	3
151	THU0292â€¦Diagnostic experiences of patients with psoriatic arthritis: misdiagnosis is common. , 2018, , .		0
152	SAT0221â€¦Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. , 2018, , .		1
153	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	1.0	93
154	Psoriasis and comorbid diseases. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 377-390.	0.6	706
155	Psoriasis and comorbid diseases. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 393-403.	0.6	152
156	Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 521-525.	0.5	77
157	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.5	194
158	The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 882-885.	0.5	62
159	Tumor necrosis factor inhibitors in psoriatic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 899-910.	1.3	34
160	Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: Benefits and Challenges of Combined Rheumatology-dermatology Clinics. <i>Journal of Rheumatology</i> , 2017, 44, 693-694.	1.0	33
161	International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 684-685.	1.0	4
162	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	1.0	42

#	ARTICLE	IF	CITATIONS
163	Tackling Patient Centricity: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 703-705.	1.0	7
164	Increased prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1674-1680.	1.3	14
165	Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 907-911.	0.9	59
166	The Changing Face of Clinical Trials in Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2017, 19, 21.	2.1	29
167	The preclinical phase of PsA: a challenge for the epidemiologist. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1481-1483.	0.5	22
168	Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard. <i>Arthritis and Rheumatology</i> , 2017, 69, 429-438.	2.9	93
169	Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study. <i>Arthritis Care and Research</i> , 2017, 69, 51-57.	1.5	98
170	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , 2016, 68, 667-672.	1.5	48
171	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. <i>RMD Open</i> , 2016, 2, e000217.	1.8	35
172	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 965-969.	1.0	24
173	Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 970-973.	1.0	6
174	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	2.9	726
175	Patient-Reported Outcomes in Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 265-283.	0.8	46
176	2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2557-2568.	2.9	393
177	Barriers to and Facilitators of a Career as a Physician-Scientist Among Rheumatologists in the US. <i>Arthritis Care and Research</i> , 2015, 67, 1191-1201.	1.5	17
178	Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 237.	0.8	18
179	Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 451-459.	0.3	11
180	Prevalence and risk factors for patient-reported joint pain among patients with HIV/Hepatitis C coinfection, Hepatitis C mono-infection, and HIV mono-infection. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 93.	0.8	12

#	ARTICLE	IF	CITATIONS
181	Enhanced Patient Involvement and the Need to Revise the Core Set Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2198-2203.	1.0	34
182	Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015, 42, 1048-1051.	1.0	6
183	Distinctions Between Diagnostic and Classification Criteria?. <i>Arthritis Care and Research</i> , 2015, 67, 891-897.	1.5	386
184	Recognizing and managing comorbidities in psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 118-126.	2.0	146
185	2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1789-1798.	0.5	545
186	Psoriasis and Cardiovascular Risk: Strength in Numbers Part 3. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2148-2150.	0.3	36
187	Reliability and Validity of Cutaneous Sarcoidosis Outcome Instruments Among Dermatologists, Pulmonologists, and Rheumatologists. <i>JAMA Dermatology</i> , 2015, 151, 1317.	2.0	21
188	Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence. <i>Current Rheumatology Reports</i> , 2015, 17, 64.	2.1	55
189	The Epidemiology of Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 545-568.	0.8	354
190	Imaging modalities for the classification of gout: systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1868-1874.	0.5	145
191	Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 326-332.	0.5	373
192	Amyloid arthropathy associated with multiple myeloma: polyarthritis without synovial infiltration of CD20+ or CD38+ cells. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 28-34.	1.4	11
193	AB0826 Imaging Modalities for the Classification of Gout: Systematic Literature Review and Meta-Analysis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1076.2-1076.	0.5	8
194	Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 918-922.	0.9	48
195	Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. <i>Rheumatology</i> , 2014, 53, 346-352.	0.9	129
196	Comprehensive Treatment of Psoriatic Arthritis: Managing Comorbidities and Extraarticular Manifestations. <i>Journal of Rheumatology</i> , 2014, 41, 2315-2322.	1.0	66
197	Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 149-153.	0.5	96
198	Psoriasis Severity and the Prevalence of Major Medical Comorbidity. <i>JAMA Dermatology</i> , 2013, 149, 1173.	2.0	402

#	ARTICLE	IF	CITATIONS
199	Epidemiology and Natural History of Psoriatic Arthritis: an Update What Dermatologists Need to Know. <i>Current Dermatology Reports</i> , 2013, 2, 66-76.	1.1	10
200	Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease. <i>Leukemia and Lymphoma</i> , 2013, 54, 1235-1241.	0.6	5
201	Teaching about how doctors think: a longitudinal curriculum in cognitive bias and diagnostic error for residents. <i>BMJ Quality and Safety</i> , 2013, 22, 1044-1050.	1.8	75
202	Amyloid arthropathy associated with multiple myeloma: A systematic analysis of 101 reported cases. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 405-412.	1.6	33
203	Prevalence and treatment patterns of psoriatic arthritis in the UK. <i>Rheumatology</i> , 2013, 52, 568-575.	0.9	118
204	Insomnia From Disease or Disaster?. <i>Academic Medicine</i> , 2013, 88, 436.	0.8	0
205	Light and Electron Microscopic Features of Synovium in Patients with Psoriatic Arthritis. <i>Ultrastructural Pathology</i> , 2012, 36, 207-218.	0.4	6
206	Obesity and the risk of psoriatic arthritis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1273-1277.	0.5	239
207	Seen Through Their Eyes. <i>Academic Medicine</i> , 2012, 87, 1361-1367.	0.8	77
208	Comparison of expectations of physicians and patients with rheumatoid arthritis for rheumatology clinic visits: a pilot, multicenter, international study. <i>International Journal of Rheumatic Diseases</i> , 2012, 15, 380-389.	0.9	35
209	Evolving role of FDG PET imaging in assessing joint disorders: a systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1939-1955.	3.3	22
210	A roadmap for education to improve the quality of care in gout. <i>Current Opinion in Rheumatology</i> , 2010, 22, 173-180.	2.0	20
211	Synovial Biopsy Findings in Arthritis Associated with Hepatitis C Virus Infection. <i>Journal of Rheumatology</i> , 2010, 37, 1361-1363.	1.0	5
212	Identification of Risk Factors for Psoriatic Arthritis. <i>Archives of Dermatology</i> , 2010, 146, 785-8.	1.7	24
213	Identification of broadly discriminatory tissue biomarkers of synovitis with binary and multicategory receiver operating characteristic analysis. <i>Biomarkers</i> , 2010, 15, 183-190.	0.9	15
214	Increased angiogenesis and cellular proliferation as hallmarks of the synovium in chronic septic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 1137-1146.	6.7	18
215	Subintimal Ki-67 as a synovial tissue biomarker for inflammatory arthropathies. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 162-167.	0.5	43
216	3'-Exonuclease resistance of DNA oligodeoxynucleotides containing O6-[4-oxo-4-(3-pyridyl)butyl]guanine. <i>Nucleic Acids Research</i> , 2003, 31, 1984-1994.	6.5	17

#	ARTICLE	IF	CITATIONS
217	Locating Nucleobase Lesions within DNA Sequences by MALDI-TOF Mass Spectral Analysis of Exonuclease Ladders. <i>Chemical Research in Toxicology</i> , 2001, 14, 1058-1070.	1.7	39